# v4.24\n\n## Related releases\n\n## Data changes\n

### Gene

```
AIP Summary Updated
AIP Background Updated
CASR Background Updated
CASR Summary Updated
GEN1 Background Updated
GEN1 Summary Updated
```

### Alteration

```
ALK HIP1-ALK Fusion, Mutation Effect, Description Updated
ALK HIP1-ALK Fusion, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
ALK HIP1-ALK Fusion, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
ALK HIP1-ALK Fusion Added
BCL10 R58Q, Mutation Effect, Description Updated
BCL10 S136*, Mutation Effect, Description Updated
BCL10 S136*, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
BCL10 S136*, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
BCL10 S136* Added
BRCA1 1731_splice [X1731_splice] Added
RNF43 G659fs*41, Mutation Effect, Description Updated
RNF43 G659fs*41, Mutation Effect, Effect Updated
	 New: Inconclusive
	 Old: Likely Neutral
RNF43 G659fs*41, Mutation Effect, Oncogenic Updated
	 New: Inconclusive
	 Old: Likely Neutral
```

### Evidence

```
AIP Gene Type, Oncogene Updated
AIP Gene Type, Tumor Suppressor Updated
CASR Gene Type, Oncogene Updated
CASR Gene Type, Tumor Suppressor Updated
ERBB2 Amplification, Breast Cancer, Summary Updated
ERBB2 Amplification, Breast Cancer, Ado-Trastuzumab Emtansine, Description Updated
ERBB2 Amplification, Breast Cancer, Ado-Trastuzumab Emtansine, Additional Information Updated
ERBB2 Amplification, Biliary Tract Cancer, NOS, Zanidatamab, Description Updated
ERBB2 Amplification, Biliary Tract, Summary Updated
ERBB2 Amplification, Biliary Tract, Zanidatamab, FDA Level Updated
	 New: Fda3
	 Old: no
ERBB2 Amplification, Biliary Tract, Zanidatamab, Level Updated
	 New: 3A
	 Old:
ERBB2 Amplification, Biliary Tract, Zanidatamab, Propagation to Other Liquid Tumor Types Updated
ERBB2 Amplification, Biliary Tract, Zanidatamab, Propagation to Other Solid Tumor Types Updated
ERBB2 Amplification, Biliary Tract, Zanidatamab 3A Added
ERBB2 Amplification, Breast Cancer, Trastuzumab + Pertuzumab + Chemotherapy, Description Updated
ERBB2 Amplification, Other Tumor Types Deleted
JAK2 PCM1-JAK2 Fusion, Myeloid, Lymphoid Neoplasms with PCM1-JAK2, Summary Updated
NRG1 Fusions, All Solid Tumors, Zenocutuzumab, Description Updated
NRG1 Fusions, Non-Small Cell Lung Cancer, Summary Updated
NRG1 Fusions, Non-Small Cell Lung Cancer, Zenocutuzumab, Description Updated
NRG1 Fusions, Non-Small Cell Lung Cancer, Zenocutuzumab, FDA Level Updated
	 New: Fda2
	 Old: no
NRG1 Fusions, Non-Small Cell Lung Cancer, Zenocutuzumab, Level Updated
	 New: 1
	 Old:
NRG1 Fusions, Non-Small Cell Lung Cancer, Zenocutuzumab, Propagation to Other Liquid Tumor Types Updated
NRG1 Fusions, Non-Small Cell Lung Cancer, Zenocutuzumab, Propagation to Other Solid Tumor Types Updated
NRG1 Fusions, Non-Small Cell Lung Cancer, Zenocutuzumab 1 Added
NRG1 Fusions, Pancreatic Adenocarcinoma, Summary Updated
NRG1 Fusions, Pancreatic Adenocarcinoma, Zenocutuzumab, Description Updated
NRG1 Fusions, Pancreatic Adenocarcinoma, Zenocutuzumab, FDA Level Updated
	 New: Fda2
	 Old: no
NRG1 Fusions, Pancreatic Adenocarcinoma, Zenocutuzumab, Level Updated
	 New: 1
	 Old:
NRG1 Fusions, Pancreatic Adenocarcinoma, Zenocutuzumab, Propagation to Other Liquid Tumor Types Updated
NRG1 Fusions, Pancreatic Adenocarcinoma, Zenocutuzumab, Propagation to Other Solid Tumor Types Updated
NRG1 Fusions, Pancreatic Adenocarcinoma Added
NRG1 Fusions, Pancreatic Adenocarcinoma, Zenocutuzumab 1 Added
```
